Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610717-25-000045
Filing Date
2025-03-04
Accepted
2025-03-04 16:33:20
Documents
1
Period of Report
2025-02-28

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 4039
  Complete submission text file 0001610717-25-000045.txt   5520
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Issuer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ALIGOS THERAPEUTICS, INC. ONE CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Symons Julian A. (Reporting) CIK: 0001824727 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39617 | Film No.: 25705252